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Background: The proteasome system has a pivotal role in the control of the immune response, which
suggests that it might be involved in the pathogenesis of autoimmune disorders.
Objective: To investigate the expression profile of selected proteasomal genes in human peripheral blood
mononuclear cells in patients with a variety of autoimmune diseases compared with healthy subjects.
Methods: Real time quantitative RT-PCR was used to analyse the mRNA expression pattern of the
proteasome activator subunits PA28a and PA28b and of constitutive proteasome and interferon-c-
inducible immunoproteasome subunits in peripheral blood mononuclear cells. Simultaneously, protein
expression of selected proteasome subunits was quantified by immunoblotting.
Results: Under systemic inflammatory conditions the proteasome subunits LMP2 (b1i), LMP7 (b5i), MECL1
(b2i), and PA28a were expressed abundantly at the protein level in the vast majority of systemic
autoimmune disorders. However, simultaneous mRNA and protein quantification showed a characteristic
proteasome expression signature in primary Sjo¨gren’s syndrome. At the transcript level, the interferon-c-
responsive subunits LMP2 (b1i), MECL1 (b2i), and the proteasome activator subunit PA28a were markedly
up regulated. In contrast, LMP2 (b1i) deficiency was evident at the protein level, indicating deregulation of
proteasome expression in Sjo¨gren’s syndrome.
Conclusions: These data provide evidence for a regulatory defect in the proteasome system in human
autoimmune disorders, pointing to a unique role for LMP2 (b1i) in the pathogenesis of primary Sjo¨gren’s
syndrome.
T
he proteasome is involved in the regulation of essential
cellular processes such as transcription, cell cycle
progression, differentiation, apoptosis, and, additionally,
in the control of stress and immune responses.1 The central
role of the proteasome implies that it may have a primary or
secondary role in the pathogenesis of different degenerative,
metabolic, and autoimmune diseases. However, our knowl-
edge about the structural and functional properties of the
proteasome system under these conditions is limited.
The eukaryotic 26S proteasome is composed of the multi-
subunit and multicatalytic 20S core complex and two 19S
regulator complexes that assist in binding and unfolding
ubiquitinylated protein substrates.2 The proteolytic activity
resides in the b1, b2, and b5 subunits.3 The proinflammatory
cytokine interferon c (IFNc) induces expression of the
proteasome activator PA28ab4 and three additional, alter-
native catalytic proteasome subunits, low molecular weight
protein (LMP)2 (b1i), multicatalytic endopeptidase complex-
like 1 (MECL1 (b2i)), and LMP7 (b5i). These subunits
replace the constitutive catalytic subunits b1, b2, and b5 in
newly formed immunoproteasomes5 6 and may alter protea-
somal protein processing qualitatively and quantitatively.1 7
Whereas LMP2 (b1i) and LMP7 (b5i) are encoded in the
major histocompatibility complex (MHC) class II region,8 9
the gene for MECL1 (b2i) is localised on human chromosome
16 in a cluster of unrelated genes.10 PA28 consists of two
subunits PA28a and PA28b, probably forming an a3b4
complex11 that accelerates and enhances a subset of certain
MHC class I epitopes in vitro and in vivo by binding to the
outer a-rings of the 20S proteasome.12
The first evidence for the potential involvement of the
proteasome in autoimmune disorders was provided by the
detection of autoantibodies directed against different protea-
some components.13–16 Autoantibodies against the protea-
some activator subunit PA28a were also found in systemic
lupus erythematosus (SLE) and Sjo¨gren’s syndrome.17 The
proteasome was identified as a major autoantigen in multiple
sclerosis18 and in young patients with type 1 diabetes
mellitus.19 Although the presence of autoantibodies does
not necessarily imply the involvement of the targeted antigen
in the disease process and might represent a bystander
phenomenon, circulating proteasomal components may be
markers of cell damage and immunological activity in
autoimmune diseases.20
Deregulation and aberration of proteasomal pathways
contribute to the pathogenesis of human diseases such as
malignant, degenerative, metabolic, and autoimmune dis-
orders.21 Regarding autoimmunity, the proteasome has a
pivotal role in the MHC class I presentation pathway of
endogenous antigens. However, detailed proteasomal gene
and protein expression in autoimmune patients in compar-
ison with healthy subjects has not been simultaneously
monitored yet. In the present study, we have focused on
the expression profiling of selected proteasomal genes in
healthy and autoimmune conditions. The analysis at the
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transcriptional level as well as the protein expression level
allowed us to identify distinct gene regulation mechanisms in
individual autoimmune disorders.
PATIENTS AND METHODS
Patients
The study included 45 patients who were diagnosed at the
Department of Rheumatology and Clinical Immunology,
Charite´-University Medicine Berlin from 1997 to 2000 with
the following autoimmune disorders: 26 patients with SLE
(23 female, 3 male, mean age at time of analysis 45.5 years,
age range 25–70 years) meeting the revised American College
of Rheumatology criteria,22 six patients with primary
Sjo¨gren’s syndrome (pSS) (female, mean age 56.3 years,
age range 31–64 years) diagnosed according to the criteria of
the European Study Group on Diagnostic Criteria for
Sjo¨gren’s Syndrome,23 four patients with systemic sclerosis
(SSc) (three female, one male, mean age 57.5 years, age
range 36–72 years) classified according to the preliminary
criteria for the classification of SSc (scleroderma),24 four
patients with polymyositis (PM) (two female, two male,
mean age 46.0 years, age range 41–53 years) meeting the
criteria according to Bohan and Peter,25 26 three patients with
rheumatoid arthritis (RA) (one female, two male, mean age
61.0 years, age range 45–69 years) diagnosed according to
the revised American College of Rheumatology criteria,22 and
two patients with ANCA associated primary vasculitis
(female, mean age 49 years, 42 and 56 years) fulfilling the
diagnostic criteria according to Jennette et al.27
At the time of blood sample collection, 15 patients with
SLE received an immunosuppressive drug (azathioprine
n = 10, cyclophosphamide n = 1, mycophenolate mofetil
n = 1, hydroxychloroquine n = 3) in addition to corticoids
(12 patients with low dose prednisolone ,10 mg/day, two
patients with prednisolone of ,50 mg/day, and one patient
with methylprednisolone 750 mg/day). The remaining 11
patients with SLE as well as all patients with pSS were
treated with low dose corticoids. Three patients with SSc
obtained low dose corticoids, one of them in combination
with azathioprine. One patient with SSc had no immuno-
suppressant drugs. Two patients with PM received immuno-
suppressive treatment (one with azathioprine and one with
cyclophosphamide) in addition to low dose prednisolone. All
patients with RA received low dose corticosteroids. Patients
with vasculitis were treated with corticoids and cyclophos-
phamide. Informed consent was obtained from all donors
before peripheral blood was taken. The study was approved
by the ethics committee of the Charite´-University Medicine,
Humboldt University, Berlin, Germany.
Preparation of peripheral blood mononuclear cells
(PBMCs)
PBMCs were isolated immediately after taking heparinised
blood by density gradient centrifugation using Ficoll
Separating Solution (Biochrom, Berlin, Germany). PBMCs
from 22 healthy blood donors (Institute for Transfusion
Medicine, Charite´-University Medicine Berlin) were used as
age and sex matched controls.
Cell culture and IFNc stimulation
JOSK-M cells derived from human PBMCs from a patient
with chronic myeloid leukaemia were obtained from the
German Collection of Micro-organisms and Cell Cultures,
DSMZ, Braunschweig, No ACC 30.28 Suspension cultures of
JOSK-M cells were maintained in RPMI 1640 (Gibco BRL,
Eggenstein, Germany) containing 10% fetal calf serum. For
IFNc treatment (Sigma, Deisenhofen, Germany), the med-
ium was supplemented with 20 and 600 U/ml IFNc respec-
tively, for 72 hours.
Table 1 Primers and probes for real time quantitative RT-PCR
Protein/GeneBank
accession No Name
Length
(bp)
Tm
( C˚)
GC
(%)
Exon
boundary Sequence
LMP2 (b1i)/U01025 2F 22 60 50 59-CGTTGTGATGGGTTCTGATTCC-39
2R 23 59 48 59-GACAGCTTGTCAAACACTCGGTT-39
2P 22 70 68 Ex2/Ex3 59-FAM-CACCGCCTC|GCCTGCAGACACT-TAMRA-39
LMP7 (b5i)/U17496 7F 18 60 67 59-GCAGTGGATTCTCGGGCC-39
7R 24 60 50 59-GCCAAGCAGGTAAGGGTTAATCTC-39
7P 30 69 53 Ex2/Ex3 59-FAM-AGCTGGGTCCTACATTA|GTGCCTTACGGGT-TAMRA-39
MECL1 (b2i)/NM_002801 MF 19 60 63 59-GCTGCGGACACTGAGCTCA-39
MR 20 60 55 59-TGGTTCCAGGCACAAAGTGG-39
MP 25 70 64 Ex7/Ex8 59-FAM-CCACAGAGCCCGTGAAGAG|GTCTGG-TAMRA-39
PA28a/U10360 ALPHA-F 19 59 53 59-TCCTTCTGCAGCGCTTGAA-39
ALPHA-R 22 60 55 59-CTCAATCCGAGGTATCTGCAGC-39
ALPHA-P 26 69 58 Ex6/Ex7 59-FAM-CAGCTCAACCTG|GTCACCACCTGGTT-TAMRA-39
PA28b/D45248 BETA-F 15 60 80 59-GTGCGCCTGAGCGGG-39
BETA-R 23 61 48 59-TCAGCCTCCTGGAAAAGATTCTG-39
BETA-P 26 70 58 Ex1/Ex2 59-FAM-AAGCCCGCAAACAG|GTGGAGGTCTTC-TAMRA-39
C3 (a2)/D00760 3F 25 60 40 59-GATTGAATATGCTTTGGCTGCTGTA-39
3R 29 60 31 59-GGATTTCTGTTTTTTCTCAGTTGCTAATA-39
3P 28 70 46 Ex2/Ex3 59-FAM-TCCGTGGGAATTAAAG|CTGCAAATGGTG-TAMRA-39
C9 (a3)/D00763 9F 23 59 52 59-GTGAGCAGTTGGTTACAGCACTG-39
9R 24 61 42 59-CAGCCAATGTACAGCAATGAAACA-39
9P 33 69 42 Ex1/Ex2 59-FAM-CAAGCTTATACACAATTTGG|AGGAAAACGTCCC-TAMRA-39
HPRT/NM_000194 HPRT-F 22 59 50 59-GACTTTGCTTTCCTTGGTCAGG-39
HPRT-R 25 59 44 59-AGTCTGGCTTATATCCAACACTTCG-39
HPRT-P 26 70 50 Ex6/Ex7 59-FAM-TTTCACCAGCAAG|CTTGCGACCTTGA-TAMRA-39
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Real time quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis
Total RNA was extracted from PBMCs and JOSK-M cells by
the TRIzol method (TRIzol reagent, PEQLAB, Erlangen,
Germany). RNA (1 mg) was DNase-I digested (Roche, Basel,
Switzerland) and reverse transcribed using Moloney murine
leukaemia virus reverse transcriptase (Gibco). Real time
quantitative RT-PCR analysis was performed using the ABI
Prism 7700 Sequence Detection System (PE Applied
Biosystems, Weiterstadt, Germany). Amplification reactions
contained TaqMan Universal PCR Master Mix (PE Applied
Biosystems), 50–900 nM forward and reverse primers in
experimentally established optimal ratios, 200 nM 59-FAM-
39-TAMRA labelled probe (BioSource Europe, Nivelles,
Belgium), and about 250 ng of cDNA. Table 1 lists the
primers (F, forward, R, reverse) and probes (P), which were
designed using the PrimerExpress software (PE Applied
Biosystems). Probes were chosen to span exon junctions of
neighbouring exons, which are indicated by a vertical bar (|).
The TaqMan PCR conditions for all amplifications were 40
cycles at 95 C˚ for 15 seconds and 60 C˚ for 1 minute, with
initial steps of 2 minutes at 50 C˚ and 10 minutes at 95 C˚.
Non-template controls for individual amplicons were
included in each run. Specificity and quality of the PCR
products were confirmed by agarose gel electrophoresis.
Standard curves were generated for each gene measured
using cDNA from healthy controls. Expression of the target
gene relative to the reference gene hypoxanthine phospho-
ribosyl transferase (HPRT) was calculated as the difference
between threshold cycles of these two genes (22DCt) using
the comparative Ct (threshold cycle) method.29 Differences
between duplicate Ct values were always (0.5. The relative
mRNA expression in autoimmune patients versus the
expression in healthy control subjects was calculated accord-
ing to the 22DDCt method.29
Western blot analysis
PBMCs were lysed on ice in 1/100 volume 10% Triton X-100
(final concentration 0.1%). Total protein (30 mg ) in each
lane was fractionated by 15% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis and transferred to
nitrocellulose, which was incubated with the following
primary antibodies (1:1000) for 1 hour at room temperature:
polyclonal rabbit antisera against the proteasome subunits C3
(a2), C9 (a3), LMP2 (b1i), LMP7 (b5i), MECL1 (b2i), and
PA28a.30 31 The secondary antibody was a horseradish
peroxidase conjugated, affinity purified goat antirabbit IgG
Fc fragment (Dianova, Hamburg, Germany, 1: 20 000).
Protein immunoreactivity was visualised by enhanced
electrochemiluminescence (ECL; Amersham, Freiburg,
Germany). Specific bands were quantified with the NIH
image 1.61 software tool (http://rsb.info.nih.gov/nih-image/,
accessed 18 May 2006) with integrated density scanning and
normalised to the constitutive subunit C3 (a2).
Evaluation of gene expression and statistical analysis
The relative expression software tool REST31a was used for
group-wise comparison and statistical analysis of the real
time quantitative RT-PCR results. REST analysis included an
efficiency correction step and Ct values normalised to HPRT
in order to compensate for variation between RT-PCR
analyses or variation from sample to sample. For the analysis
of protein expression levels, significance was assessed by a
two sided Student’s t test or Mann-Whitney U test where
appropriate (*p,0.05, **p,0.01, ***p,0.001).
RESULTS
Real time RT-PCR analysis of selected
immunoproteasome and proteasome activator subunit
expression after IFNc up regulation in vitro
A real time quantitative RT-PCR assay was established in
order to investigate the gene expression of selected protea-
some and proteasome activator subunits. Similar PCR
amplification efficiencies of control and target genes were
confirmed using serial dilutions of cDNA from human control
PBMCs. These experiments were conducted to obtain
standard curves as the prerequisite for the 22DDCt method.29
When the quantitative RT-PCR system was established, the
assay was verified in an in vitro IFNc stimulation experiment.
JOSK-M cells from a human chronic myeloid leukaemia cell
line were stimulated for 72 hours with 20 and 600 U/ml
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Figure 1 Real time RT-PCR analysis of proteasome and proteasome activator subunit expression after IFNc induction in vitro. JOSK-M cells were
treated with IFNc for 72 hours (20 U/ml, white bars; 600 U/ml grey bars). Untreated JOSK-M cells served as controls (black bars). The non-
proteasomal housekeeping gene HPRT was used as a reference. Relative expression values were calculated based on the PCR amplification efficiencies
E of the individual amplicons. The values (EDCt) are given as relative mRNA expression. Values are given as means (SEM) Significance was assessed by
two sided Student’s t test (*p,0.05, **p,0.01).
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IFNc, respectively (fig 1). Untreated JOSK-M cells served as
controls for basal expression levels. The mRNA expression of
LMP2, LMP7, MECL1, C3, C9, PA28a, and PA28b was
determined. The expression of HPRT was measured as a
control gene unrelated to the proteasome system.32 After
normalisation to the respective housekeeping gene, the
individual data (DCt values) were converted to a linear form
considering the PCR doubling efficiency E of each amplicon.
After IFNc stimulation of JOSK-M cells, the relative mRNA
expression of the inducible immunoproteasome subunits and
the expression of the activator subunits PA28a and PA28b
were increased significantly compared with untreated
control cells (fig 1). The expression of the constitutive
subunits C3 and C9 and the housekeeping gene HPRT
remained stable. Normalisation to HPRT, C3 or C9 demon-
strated significant up regulation of the immunoproteasome
–1.3
Re
la
tiv
e 
m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 H
PR
T 
(S
EM
))
Re
la
tiv
e 
m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 H
PR
T 
(S
EM
))
Re
la
tiv
e 
m
RN
A
 e
xp
re
ss
io
n
(fo
ld
 H
PR
T 
(S
EM
))
C
t v
al
ue
s 
(S
EM
)
60
80
40
20
0
RA
2.2
LMP2 (β1i)A
VascSScPMpSSSLEC
600
800
400
200
0
RA
MECL1 (β2i)C
VascSScPMpSS
3.9
SLEC
10
12
8
6
0
2
RA
LMP7 (β5i)B
4
VascSScPMpSSSLEC
300
200
250
150
100
0
50
RA
PA28αD
VascSScPMpSSSLEC
300
200
250
150
100
0
50
RA
PA28βE
VascSScPMpSS
2.6 2.4 3.3
1.7
2.1
SLEC
20
15
10
0
5
RA
C3 (α2)F
VascSScPMpSSSLEC
32
10
12
RA
HPRTH
VascSScPMpSSSLEC
20
15
10
0
5
RA
C9 (α3)G
VascSScPM
–1.8
pSSSLEC
2.2
2.5
2.4 1.9
1.6 14
16
18
20
22
24
26
28
30
Figure 2 Proteasomal gene expression profiling in autoimmune patients. Gene expression of IFNc-inducible immunoproteasome subunits (A, B, C),
proteasome activator subunits (D, E), and two selected constitutive proteasome subunits (F, G) was measured by real time quantitative RT-PCR in PBMCs
from patients with SLE (n = 26), pSS (n = 6), PM (n = 4), SSc (n = 4), RA (n = 3), and primary vasculitis (Vasc; n = 2) showing clinically active disease.
Healthy blood donors served as age and sex matched controls (C; n = 22). Only significant relative up regulation>1.6-fold was discussed. Patients with
vasculitis and RA were not included in the statistical evaluations owing to the small number of cases. Values are given as the mean (SEM) relative mRNA
expression. If applicable, a two sided Mann-Whitney U test was used to verify statistical significance (*p,0.05, **p,0.01, ***p,0.001).
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Figure 3 Expression profile of LMP2 (b1i) in autoimmune disorders by immunoblot analysis of PBMC lysates. Representative data are shown for SLE
(n = 7, lanes 1–7), pSS (n = 6, lanes 8–13), SSc (n = 4, lanes 14–17), PM (n = 4, lanes 18–21), and healthy controls (n = 6, lanes 22–27). Cell lysates
were normalised for protein (30 mg total protein per lane) and analysed by immunoblotting with antibodies against LMP2 (b1i) and the constitutive
human proteasome subunits C3 (a2). Note that lanes 8–13 were slightly overexposed in order to demonstrate reduced LMP2-specific signals in most
patients with pSS.
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and the proteasome activator subunits after IFNc stimulation
(data not shown).
mRNA expression of constitutive,
immunoproteasome, and proteasome regulator
subunits is differentially up regulated in autoimmune
conditions
Gene expression was measured in PBMCs taken from
patients with systemic autoimmune disorders such as SLE
(n = 26), pSS (n = 6), PM (n = 4), RA (n = 3), SSc (n = 4),
and primary vasculitis (n = 2) showing clinically active
disease (fig 2). PBMCs from healthy blood donors served as
controls (n = 22). Relative mRNA expression of the consti-
tutive proteasome subunits C3 and C9, the immunoprotea-
some subunits LMP2, LMP7, and MECL1, the activator
subunits PA28a and PA28b, and the housekeeping gene
HPRT was measured. Figure 2 shows the mean (SEM)
relative mRNA expression of each diagnosis group.
In pSS, a strong simultaneous up regulation of the IFNc-
inducible subunits LMP2 (fig 2A), MECL1 (fig 2C), and
PA28a (fig 2D) was detectable at the mRNA level. As a
common feature, PA28b was significantly up regulated in
patients with connective tissue diseases (fig 2E). In RA, we
observed that MECL1 was the only homogeneously up
regulated, inducible subunit (fig 2C). Interestingly, the
expression levels of the immunosubunit LMP7 were similar
in controls and patients (fig 2B). An increased expression of
the constitutive proteasomal subunit C3 was noted at the
mRNA level in all autoimmune diseases (fig 2F), whereas the
other constitutive subunit C9 was found in a similar or
reduced range compared with controls (fig 2G). In vasculitis,
the expression levels of the IFNc-inducible subunits were not
significantly altered. Except for RA (n = 3), plotting the mean
Ct values for HPRT demonstrated largely stable expression of
the reference gene (fig 2H).
In patients with SLE no significant differences were found
for mRNA expression of any of the investigated proteasome
subunits in PBMCs when patients with low dose corticoid
treatment were compared with patients who received
additive immunosuppressive treatment.
Regulation of proteasomal protein expression in
autoimmune disorders
In another set of experiments we investigated whether
differential regulation of proteasomal expression at the
transcript level was also reflected by the protein expression
of constitutive or immunoproteasome subunits in PBMCs in
autoimmune disorders. Protein expression was analysed in
crude PBMC lysates (30 mg total protein) from all auto-
immune patients whose mRNA expression had been quanti-
fied previously (compare fig 2). C3, C9, LMP2, LMP7, MECL1,
and PA28a protein expression was analysed by western
blotting. Representative immunoblots are shown for LMP2
protein expression (fig 3). The LMP2 signal was similar in all
22 healthy control subjects and 39 patients investigated
except for the majority of patients with pSS (fig 3 and data
not shown).
Specific protein bands were quantified by densitometry
and normalised to C3 protein expression. C3 levels allow a
good estimate of total functional proteasome in a cell. The
mean protein expression was shown for LMP2 (fig 4A),
LMP7 (fig 4B), MECL1 (fig 4C), and PA28a (fig 4D). The data
indicate that LMP7, MECL1, and PA28a were abundantly
expressed in PBMCs. In comparison with healthy controls,
LMP2 protein levels were significantly decreased in the
majority of patients with pSS (5 out of 6) but not in other
autoimmune patients (n = 39) (fig 3, 4A, and data not
shown). Individual treatment in patients with SLE (low dose
corticoid monotherapy versus corticoid and add-on immuno-
suppressant drugs) had no significant effect on protein
expression of LMP2, LMP7, MECL1, or PA28a in PBMCs.
DISCUSSION
The present study provides evidence for a disturbed expres-
sion of components in the proteasome system at both the
mRNA and the protein level in human autoimmune
disorders. Interestingly, we found characteristic expression
profiles for distinct autoimmune diseases. We substantiated
the strong induction of IFNc-inducible proteasomal subunits
as well as of the proteasome activator in systemic auto-
immune diseases at the mRNA level. However, increased
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mRNA expression of certain proteasome subunits did not
correspond directly with their respective protein expression.
The observed gene regulation patterns are in good
agreement with established pathways of proteasome regula-
tion, assembly, and maturation in vitro.5 6 Conceivably, in
autoimmune conditions components of the proteasomal
system are induced by proinflammatory cytokines such as
IFNc. Moreover, LMP7 is expressed in lymphoid cells and
tissues at high levels.32a Previously, it was demonstrated that
pre-proteasomes containing LMP2 and MECL1 require LMP7
for efficient maturation.5 In this context, LMP7 is up
regulated to relatively constant levels in healthy controls as
well as in autoimmune patients, which suggests individual
gene regulation mechanisms other than for LMP2 and
MECL1. This view is supported by the fact that the MECL1
gene is localised on another chromosome.10 Alternatively,
there may be a concerted regulation of both LMP2 and
MECL1 involving the IFN regulatory factor IRF-1.33
The induction of the constitutive subunit C3 was described
in human muscle tissue in septic patients.34 In accordance
with these data, C3 mRNA levels were up regulated in certain
autoimmune disorders, including connective tissue diseases
and systemic vasculitis. Therefore, we suggest that in
autoimmune patients C3 underlies differential induction
mechanisms as compared with C9. Raised C3 mRNA levels
were also found after the exposure to glucocorticoids35
probably owing to an impaired negative regulation of C3
expression by nuclear factor-kappaB (NF-kB).36 These data
imply an alternative induction mechanism of C3 mRNA
because the vast majority of the autoimmune patients in this
study obtained steroid immunosuppression. In this study, no
difference was found between the respective immunosup-
pressive treatment and the expression of any of the
investigated proteasome subunits at the mRNA level in
patients with SLE.
Surprisingly, in contrast with the other autoimmune
disorders, our data disclosed a significant up regulation of
the IFNc-inducible subunits LMP2, MECL1, and PA28a at the
mRNA level in patients with pSS. On the other hand, the
protein level of LMP2 was very low in most patients with pSS
compared with healthy controls and other related auto-
immune disorders. This intriguing finding was obtained in a
small, but homogenous pSS study group. Increased mRNA
levels of LMP2 may reflect (a) increased mRNA steady state
levels, (b) increased mRNA stability, or (c) an increased
transcription rate. Whereas increased mRNA levels in other
autoimmune diseases correspond with the respective protein
expression levels, this correlation is reversed in pSS. The
relative lack of the subunit LMP2 might be due to raised C3
levels. However, the protein expression of C3 was not
markedly increased in pSS. A decrease of LMP2 protein
might result from (a) a post-transcriptional defect of the
LMP2 mRNA, (b) an impaired translation process, or (c)
reduced protein stability of LMP2. The proteasome system is
important for T cell education and antigen presentation by
MHC class I molecules.37 Although experimental evidence has
not been provided up to now, decreased LMP2 protein levels
may contribute to an altered composition of the proteasome
population in PBMCs of patients with pSS. As a consequence,
the MHC class I peptide repertoire of antigen presenting cells
in the periphery may be changed both qualitatively and
quantitatively and might promote autoimmune pathogenesis.
A specific proteasome defect has been identified in non-
obese diabetic (NOD) mice, an animal model of autoimmune
diabetes, in lymphocytic and monocytic lineages, resulting in
the down regulation of LMP2 expression.38 It has been
suggested that the molecular defect resides within the
promoter-enhancer region of LMP2, which results in
decreased mRNA levels of LMP2. This defect may prevent
proteolytic proteasomal processing of NF-kB, affecting
immune and inflammatory responses, as well as suscept-
ibility to apoptosis induced by tumour necrosis factor a.
Interestingly, NOD mice provide a suitable model of Sjo¨gren’s
syndrome, in particular autoimmune sialadenitis exhibiting
exocrine gland lymphocytic infiltration typical of the
Sjo¨gren’s syndrome-like disease.39
Our findings cannot simply be explained by a transcrip-
tional defect in the LMP2 gene in patients with pSS according
to the NOD mouse model, because LMP2 mRNA was
abundant in PBMCs. Previously, it had been shown that
proteasomal subunits are up regulated at the transcriptional
level upon treatment with proteasome inhibitors.40 In
addition, there is evidence for a regulatory feedback loop,
not only in yeast but also in the mammalian proteasomal
system.41 Based on these results, we suggest that decreased
protein levels of LMP2 in PBMCs in pSS may be followed by
reactive up regulation of mRNA in the proteasomal system.
This situation appears to be unique for pSS, because in SLE,
SSc, PM, and RA transcript as well as protein levels of the
respective subunits were regulated accordingly.
For the first time, expression patterns in the proteasome
system at both the transcriptional and translational level
were analysed simultaneously in active systemic rheumatoid
disorders. Our observations showed that autoimmune dis-
eases have distinct proteasomal gene and protein expression
signatures. In this study we have provided new clues for a
unique role of LMP2 in the pathogenesis of pSS, suggesting a
regulatory molecular defect of LMP2 in pSS. Further genetic
and biochemical studies should extend our understanding of
the pathophysiology of the proteasome system, leading to
new diagnostic and therapeutic strategies in human auto-
immune disorders.
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